1.0 2009-07-30 17:58:51 UTC 2026-05-14 16:59:07 UTC T3D3501 Docetaxel SmallMolecule Docetaxel belongs to the diterpenoids, a subclass of prenol lipids within the organic compounds. With an average molecular weight of 807.88 g/mol, Docetaxel is a heavy molecule. This exogenous solid, with the formula C43H53NO14, is used as an antineoplastic agent, a photosensitizing agent, and an antimalarial. It is recorded as being found in household cleaning and consumer products such as soap dispensers, electrical and electronic equipment such as antennas, and healthcare, pharmaceuticals and veterinary products. The compound is administered intravenously and has been detected in the liver and kidney. Docetaxel is used to treat various cancers, including breast cancer (PMC10155940), prostate cancer (PMC10313599, PMC1697755), ovarian cancer (PMC10091760, PMC7676468, PMC8072532), lung cancer (PMC3383615), pancreatic cancer (PMC10003701), angiosarcoma (PMC12591960, PMC5102718), and squamous cell carcinoma (PMC10314637), as well as cancer generally (PMC3480876, PMC6102750). It has a therapeutic effect on breast cancer (PMC11173842), thyroid cancer (PMC10003701), and necrosis (PMC3834492). However, it is associated with bradycardia (decrease) (PMC6180974) and pneumonitis (PMC12273849). The compound targets nine proteins, including the apoptosis regulator Bcl-2 (BCL2), Microtubule-associated protein 2 (MAP2), Microtubule-associated protein 4 (MAP4), Microtubule-associated protein tau (MAPT), and Nuclear receptor subfamily 1 group I member 2 (NR1I2). Docetaxel specifically binds to the beta-subunit of the tubulin beta-1 chain (TUBB1), locking these building blocks and hyper-stabilizing the structure of microtubules. This action interferes with normal microtubule growth and destroys the cell's ability to use its cytoskeleton flexibly, which is the opposite effect of drugs like colchicine that cause depolymerization. Drug Synthetic Toxin Organic Compound Amine Ether Ester Drug Antineoplastic Agent Antineoplastic Agent, Phytogenic Antimalarial Radiation-Sensitizing Agent Metabolite Synthetic Compound Human Neurotoxin Docefrez Docetaxel anhydrous Docetaxel, Trihydrate N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Taxotere TXL C43H53NO14 807.8792 807.346605409 (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate 114977-28-5 [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1 InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N Organic compounds Lipids and lipid-like molecules Prenol lipids Diterpenoids Taxanes and derivatives Benzoic acid esters Benzoyl derivatives Carbamate esters Carboxylic acid esters Cyclic alcohols and derivatives Dialkyl ethers Fatty acid esters Hydrocarbon derivatives Ketones Monosaccharides Organic carbonic acids and derivatives Organic oxides Organonitrogen compounds Organopnictogen compounds Oxacyclic compounds Oxetanes Polyols Secondary alcohols Tertiary alcohols Tricarboxylic acids and derivatives Alcohol Aromatic heteropolycyclic compound Benzenoid Benzoate ester Benzoic acid or derivatives Benzoyl Carbamic acid ester Carbonic acid derivative Carbonyl group Carboxylic acid derivative Carboxylic acid ester Cyclic alcohol Dialkyl ether Ether Fatty acid ester Fatty acyl Hydrocarbon derivative Ketone Monocyclic benzene moiety Monosaccharide Organic nitrogen compound Organic oxide Organic oxygen compound Organoheterocyclic compound Organonitrogen compound Organooxygen compound Organopnictogen compound Oxacycle Oxetane Polyol Secondary alcohol Taxane diterpenoid Tertiary alcohol Tricarboxylic acid or derivatives Aromatic heteropolycyclic compounds tetracyclic diterpenoid Detected and Not Quantified Exogenous Cytoplasm Extracellular Membrane Kidney Liver Docetaxel Pathway Docetaxel Action Pathway SMP0000435 Docetaxel Action Pathway (New) SMP0124488 Docetaxel Drug Metabolism Action Pathway SMP0143666 Solid White powder. melting_point 232°C solubility Insoluble logp 2.4 logp 2.59 ALOGPS logs -4.80 ALOGPS solubility 1.27e-02 g/l ALOGPS logp 2.92 ChemAxon pka_strongest_acidic 10.96 ChemAxon pka_strongest_basic -3 ChemAxon iupac (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate ChemAxon average_mass 807.8792 ChemAxon mono_mass 807.346605409 ChemAxon smiles [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1 ChemAxon formula C43H53NO14 ChemAxon inchi InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1 ChemAxon inchikey ZDZOTLJHXYCWBA-VCVYQWHSSA-N ChemAxon polar_surface_area 224.45 ChemAxon refractivity 203.9 ChemAxon polarizability 82.15 ChemAxon rotatable_bond_count 13 ChemAxon acceptor_count 10 ChemAxon donor_count 5 ChemAxon physiological_charge 0 ChemAxon formal_charge 0 ChemAxon Intravenous injection. The pharmacokinetic profile is consistent with a three-compartment model. The area under the curve (AUC) was dose proportional following doses of 70 mg/m2 to 115 mg/m2 with infusion times of 1 to 2 hours. Docetaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, docetaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, docetaxel binds to the &beta;-subunit of tubulin. Tubulin is the 'building block' of mictotubules, and the binding of docetaxel locks these building blocks in place. The resulting microtubule/docetaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that docetaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function. Oral LD₅₀ in rat is >2000 mg/kg. Hepatic. In vitro drug interaction studies revealed that docetaxel is metabolized by the CYP3A4 isoenzyme (1 major, 3 minor metabolites). Route of Elimination: Docetaxel was eliminated in both the urine and feces following oxidative metabolism of the tert-butyl ester group, but fecal excretion was the main elimination route. Within 7 days, urinary and fecal excretion accounted for approximately 6% and 75% of the administered radioactivity, respectively. Half Life: Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively. Oral LD₅₀ in rat is >2000 mg/kg. No indication of carcinogenicity to humans (not listed by IARC). For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer. #<HealthEffect::ActiveRecord_Associations_CollectionProxy:0x00007f3bf347a1e0> Anticipated complications of overdosage include: bone marrow suppression, peripheral neurotoxicity, and mucositis. In two reports of overdose, one patient received 150 mg/m² and the other received 200 mg/m² as 1-hour infusions. Both patients experienced severe neutropenia, mild asthenia, cutaneous reactions, and mild paresthesia, and recovered without incident. DB01248 HMDB15378 148124 CHEMBL92 130581 C11231 4672 Docetaxel TXL Docetaxel FDA label BE0000956 BE0000767 Dissociation 0.00082 uM BindingDB 36351 BE0000625 IC50 0.00014 uM BindingDB 36351 BE0001852 IC50 0.00018 uM BindingDB 36351 IC50 0.0003 uM BindingDB 36351 IC50 0.00031 uM BindingDB 36351 IC50 0.0087 uM BindingDB 36351 BE0001100 BE0003475 BE0003474 BE0000246 Docetaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, docetaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, docetaxel binds to the &beta;-subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of docetaxel locks these building blocks in place. The resulting microtubule/docetaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that docetaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function. BE0000026 Docetaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, docetaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, docetaxel binds to the &beta;-subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of docetaxel locks these building blocks in place. The resulting microtubule/docetaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that docetaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.